Literature DB >> 23719242

Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Michael A Sheard1, Shahab Asgharzadeh, Yin Liu, Tsen-Yin Lin, Hong-Wei Wu, Lingyun Ji, Susan Groshen, Dean A Lee, Robert C Seeger.   

Abstract

Neuroblastoma cells have been reported to be resistant to death induced by soluble, recombinant forms of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (CD253/TNFSF10) because of low or absent expression of caspase-8 and/or TRAIL-receptor 2 (TRAIL-R2/DR5/CD262/TNFRSF10b). However, their sensitivity to membrane-bound TRAIL on natural killer (NK) cells is not known. Comparing microarray gene expression and response to NK cell-mediated cytotoxicity, we observed a correlation between TRAIL-R2 expression and the sensitivity of 14 neuroblastoma cell lines to the cytotoxicity of NK cells activated with interleukin (IL)-2 plus IL-15. Even though most NK cytotoxicity was dependent upon perforin, the cytotoxicity was supplemented by TRAIL in 14 of 17 (82%) neuroblastoma cell lines as demonstrated using an anti-TRAIL neutralizing antibody. Similarly, a recently developed NK cell expansion system employing IL-2 plus lethally irradiated K562 feeder cells constitutively expressing membrane-bound IL-21 (K562 clone 9.mbIL21) resulted in activated NK cells derived from normal healthy donors and neuroblastoma patients that also utilized TRAIL to supplement cytotoxicity. Exogenous interferon-γ upregulated expression of caspase-8 in 3 of 4 neuroblastoma cell lines and increased the contribution of TRAIL to NK cytotoxicity against 2 of the 3 lines; however, relatively little inhibition of cytotoxicity was observed when activated NK cells were treated with an anti-interferon-γ neutralizing antibody. Constraining the binding of anti-TRAIL neutralizing antibody to membrane-bound TRAIL but not soluble TRAIL indicated that membrane-bound TRAIL alone was responsible for essentially all of the supplemental cytotoxicity. Together, these findings support a role for membrane-bound TRAIL in the cytotoxicity of NK cells against neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23719242      PMCID: PMC4064791          DOI: 10.1097/CJI.0b013e31829b4493

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  35 in total

1.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.

Authors:  Eva Baader; Agnieszka Toloczko; Uta Fuchs; Irene Schmid; Christian Beltinger; Harald Ehrhardt; Klaus-Michael Debatin; Irmela Jeremias
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

3.  Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.

Authors:  Shahab Asgharzadeh; Roger Pique-Regi; Richard Sposto; Hong Wang; Yujun Yang; Hiroyuki Shimada; Katherine Matthay; Jonathan Buckley; Antonio Ortega; Robert C Seeger
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

4.  Expansion, purification, and functional assessment of human peripheral blood NK cells.

Authors:  Srinivas S Somanchi; Vladimir V Senyukov; Cecele J Denman; Dean A Lee
Journal:  J Vis Exp       Date:  2011-02-02       Impact factor: 1.355

5.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Paola Bocca; Fabio Morandi; Marta Camoriano; Claudio Gambini; Xinhui Wang; Soldano Ferrone; Vito Pistoia
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

Review 6.  Nonapoptotic functions of FADD-binding death receptors and their signaling molecules.

Authors:  Sun-Mi Park; Robert Schickel; Marcus E Peter
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

7.  Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma.

Authors:  Matthias Wölfl; Achim A Jungbluth; Federico Garrido; Teresa Cabrera; Sharon Meyen-Southard; Rüdiger Spitz; Karen Ernestus; Frank Berthold
Journal:  Cancer Immunol Immunother       Date:  2004-09-24       Impact factor: 6.968

8.  Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

Authors:  Daniela Berg; Thorsten Stühmer; Daniela Siegmund; Nicole Müller; Tina Giner; Oliver Dittrich-Breiholz; Michael Kracht; Ralf Bargou; Harald Wajant
Journal:  FEBS J       Date:  2009-11-06       Impact factor: 5.542

9.  Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis.

Authors:  A Mühlethaler-Mottet; M Flahaut; K Balmas Bourloud; K Nardou; A Coulon; J Liberman; M Thome; N Gross
Journal:  Cell Death Dis       Date:  2011-03-03       Impact factor: 8.469

10.  Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.

Authors:  Cecele J Denman; Vladimir V Senyukov; Srinivas S Somanchi; Prasad V Phatarpekar; Lisa M Kopp; Jennifer L Johnson; Harjeet Singh; Lenka Hurton; Sourindra N Maiti; M Helen Huls; Richard E Champlin; Laurence J N Cooper; Dean A Lee
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

View more
  19 in total

1.  Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Authors:  Alexandra C Vrazo; Adrianne E Hontz; Sarah K Figueira; Braeden L Butler; Julie M Ferrell; Brock F Binkowski; Jinzhu Li; Kimberly A Risma
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

2.  3-Dimensional Model to Study Apoptosis Induction of Activated Natural Killer Cells Conditioned Medium Using Patient-Derived Colorectal Cancer Organoids.

Authors:  Benyamin Parseh; Ayyoob Khosravi; Abdolreza Fazel; Jafar Ai; Somayeh Ebrahimi-Barough; Javad Verdi; Majid Shahbazi
Journal:  Front Cell Dev Biol       Date:  2022-05-26

3.  TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Authors:  Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2016-10-10       Impact factor: 12.531

Review 4.  Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Authors:  Dhifaf Sarhan; Padraig D'Arcy; Andreas Lundqvist
Journal:  Int J Mol Sci       Date:  2014-10-14       Impact factor: 5.923

5.  Metastatic colon cancer cell populations contain more cancer stem-like cells with a higher susceptibility to natural killer cell-mediated lysis compared with primary colon cancer cells.

Authors:  Ga Rim Kim; Ga-Hee Ha; Jae-Ho Bae; Sae-Ock Oh; Sun-Hee Kim; Chi-Dug Kang
Journal:  Oncol Lett       Date:  2015-01-29       Impact factor: 2.967

6.  NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis.

Authors:  P Ruggeri; L Cappabianca; A R Farina; L Gneo; A R Mackay
Journal:  Cell Death Discov       Date:  2016-02-01

7.  Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.

Authors:  Martine Cordeau; Assila Belounis; Martin Lelaidier; Paulo Cordeiro; Hervé Sartelet; Sabine Herblot; Michel Duval
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

8.  Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Authors:  Katharina Tatzel; Lindsay Kuroki; Igor Dmitriev; Elena Kashentseva; David T Curiel; S Peter Goedegebuure; Matthew A Powell; David G Mutch; William G Hawkins; Dirk Spitzer
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

9.  Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.

Authors:  Yang Su; Katharina Tatzel; Xuejun Wang; Brian Belt; Pratibha Binder; Lindsay Kuroki; Matthew A Powell; David G Mutch; William G Hawkins; Dirk Spitzer
Journal:  Oncotarget       Date:  2016-05-24

10.  Down-regulation of CHERP inhibits neuroblastoma cell proliferation and induces apoptosis through ER stress induction.

Authors:  Dunke Zhang; Feng Wang; Yi Pang; Xiao-Xue Ke; Shunqin Zhu; Erhu Zhao; Kui Zhang; Lixue Chen; Hongjuan Cui
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.